Navigation Links
Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update
Date:2/23/2012

CAMBRIDGE, Mass., Feb. 23, 2012 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the fourth quarter and year ended December 31, 2011 as well as the advancement of its hepatitis C virus (HCV) development pipeline.

Operational HighlightsIDX184 ProgramThe Company's lead program, IDX184, is a pan-genotypic oral nucleotide polymerase inhibitor for the treatment of HCV. In July 2011, Idenix initiated enrollment of treatment-naive HCV-infected patients into a 12-week phase IIb clinical trial of IDX184 in combination with pegylated interferon and ribavirin. In January 2012, the Company reported an interim analysis from this study of the first 31 patients who completed 28 days of treatment demonstrating favorable safety and antiviral activity. At 12 weeks, the Complete Early Virologic Response (cEVR < 25 IU/mL) was 93% for the 100 mg IDX184 arm (n=15) and 81% for the 50 mg IDX184 arm (n=16) of the study (intent-to-treat analysis). The side effect profile of the combined therapy has remained consistent with the known safety profile for pegylated interferon and ribavirin.

In February 2012, the U.S. Food and Drug Administration removed the partial clinical hold on IDX184 after review of the interim phase IIb data and the independent Data Safety Monitoring Board's recommendation to continue the study. The Company has now begun enrollment of an additional 30 patients under expanded enrollment criteria in the ongoing phase IIb clinical trial. Additionally, the Company anticipates implementing a broad phase IIb program with IDX184, focusing on the evaluation of interferon-free direct-acting antiviral (DAA) combination regimens, in the coming months.

IDX719 ProgramIn January 2012, the Company
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
2. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
4. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
5. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
6. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
7. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
8. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Novastem, a leader in regenerative medicine, ... its study for ischemic stroke at Clinica Santa ... strokes account for 87 percent of all stroke ... the study, entitled "Internal Research Protocol in Combination ... Cells and Intrathecal Administration of Neural Stem Cells ...
(Date:12/24/2014)... N.Y. , Dec. 24, 2014 Kinex ... dosed with KX2-361 at Roswell Park Cancer Institute. ... small molecule drug that has shown potent inhibitory activity ... including those that are resistant to Temozolomide (T98G), the ... glioma. In a well-established brain tumor mouse model, KX2-361 ...
(Date:12/24/2014)... Dec. 24, 2014  Diplomat Pharmacy, Inc. (NYSE: ... is proud to announce Jennifer Hagerman , Pharm.D., ... will take office as the president of the Michigan ... ceremony will take place Feb. 28, 2015, at the ... at the Renaissance Center in Detroit, Michigan ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3
... April 28, 2011 CardioFocus, Inc., developer of ... of Atrial Fibrillation (AF), convened international leaders in ... visualization to guide catheter ablation for the treatment ... day of the German Society for Cardiology Annual ...
... Inc. (OTC Bulletin Board: SCLR ) is pleased ... Pharma, Inc., will be presenting at Taglich Brothers 8th Annual ... will take place at the New York Athletic Club, New ... About SCOLR Pharma: Based in ...
Cached Medicine Technology:International Leaders in Electrophysiology Discuss Improving Atrial Fibrillation Treatment Using Novel Endoscopically Guided Laser Ablation Catheter 2International Leaders in Electrophysiology Discuss Improving Atrial Fibrillation Treatment Using Novel Endoscopically Guided Laser Ablation Catheter 3
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional shopping tips ... the models at LunaDress.co.uk come with big discounts, up to 80 ... can turn out to be a most exciting memory and can ... bring surprise to a wedding. On the updated fashion blog, ladies ... for a big day . , Going out with friends to ...
(Date:12/25/2014)... Thompson HealthDay Reporter WEDNESDAY, ... in on a "fountain of youth" drug that can delay ... adults, a new study suggests. Seniors received a significant ... targets a genetic signaling pathway linked to aging and immune ... The experimental medication, a version of the drug rapamycin, ...
(Date:12/25/2014)... December 25, 2014 Residents at ... Community, recently showed their generous spirit by providing ... Catawba County Parenting Network- Grandparents Raising Grandchildren program. ... gathered around the largest Christmas tree on the ... purchased by residents of the Abernethy Village Association ...
(Date:12/24/2014)... 2014 Epigenetics finds applications in a ... oncology, drug discovery, developmental biology, and research for metabolic ... of the most widely used techniques for the discovery ... prevalence of cancer is rapidly growing worldwide. In 2012, ... cancer deaths, and 32.6 million people living with cancer ...
(Date:12/24/2014)... 24, 2014 Dr. Vu Ho, a ... of his practice and med-spa with the addition of ... list of cosmetic treatments and services. , “Silk Peel ... skin,” says Dr. Ho. “As a result it can ... wrinkles, sun spots, discolorations or blemishes.” , Similar to ...
Breaking Medicine News(10 mins):Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2
... Thanks to ... Surgery Institute of Southeast Texas. Houston plastic surgeon Dr. Leo Lapuerta leads the way in Houston ... ... area and lead to impressive results, especially as summer and beach season approaches. Recovery from a ...
... ... disordered eating -- from obesity to anorexia, says specialist Dr. Stacey Rosenfeld , ... New York, NY (Vocus) -- With ... can help significantly decrease chances that kids will develop an eating disorder or have a ...
... 8 times the risk after head trauma, study finds , ... for a traumatic brain injury face an almost eight-fold higher ... of a team led by Charles H. Bombardier, professor of ... in Seattle and first author of a study published in ...
... ... Show featuring classic cars, live music, giveaways and more on Saturday, May 22, 2010 from 11:00 ... (Vocus) May ... a Classic Woody Car Show featuring classic cars, live music, giveaways and more on Saturday, May ...
... Exercise, treating hypertension may help, researchers say , TUESDAY, ... the flow of blood in the brain and lead to ... stem from research led by Dr. Farzaneh A. Sorond of ... and Harvard Medical School in Boston. , Sorond and her ...
... commonly used probe for Positron Emission Tomography (PET) scanning ... reveal different functions in diverse cells of the immune ... an immune response in action. The probes, the ... FAC, developed at UCLA and which measures the activity ...
Cached Medicine News:Health News:New On-Q Pain Pump Making Tummy Tucks Easier 2Health News:Dr. Stacey Rosenfeld Offers Tips on How to Raise a Child who has Body Confidence and a Healthy Relationship with Food 2Health News:Dr. Stacey Rosenfeld Offers Tips on How to Raise a Child who has Body Confidence and a Healthy Relationship with Food 3Health News:Major Depression Often Follows Brain Injury 2Health News:Major Depression Often Follows Brain Injury 3Health News:Retirement Community in Arizona Hosts Classic Car Show with Live Music 2Health News:Elderly Falls Linked to Altered Blood Flow in Brain 2Health News:PET scanning probes reveal different cell function within the immune system 2
... -Chagas is an in-vitro diagnostic test ... to Trypanosoma cruzi in human serum/plasma. ... particle-agglutination assay using gelatin particles coated ... coated gelatin particles are agglutinated in ...
The Cellabs T. cruzi IgG CELISA is a direct ELISA kit designed to detect antibodies produced during T. cruzi infections (Chagas disease)....
Inquire...
Silicone ICD lead...
Medicine Products: